RxDoctor Payments Data

Okeoma Chukwu, NP

Family · Athens, GANPI 1043716137

Payments from drug & device makers

$3,539in general payments, 2019–2025

Across 161 payments — averaging $21.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Neurocrine Biosciences, Inc.$583
  • Supernus Pharmaceuticals, Inc.$414
  • Lundbeck LLC$403
  • Teva Pharmaceuticals USA, Inc.$380
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$345
  • Indivior Inc.$340
  • plus $1K from 7 others

What the payments were for

  • Food & beverage$3,527100%
  • Education$120%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,539 in reported general payments places this provider in the 85th percentile of 6,258 family providers in Georgia.

See all family providers in Georgia

Medicare billing

Part B allowed, 2024
$5,384
Medicare patients
27
Services billed
71

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega SustennaPaliperidone Palmitate15$44,085
RexultiBrexpiprazole18$26,459
Abilify MaintenaAripiprazole12$23,790
Risperidone60$1,282
Aripiprazole32$1,131
Haloperidol Decanoate14$619
Hydroxyzine Pamoate52$529
Gabapentin46$470
Bupropion XlBupropion Hcl44$452
Quetiapine Fumarate96$445
Olanzapine18$418
Oxcarbazepine15$401
Duloxetine Hcl49$383
Trazodone Hcl85$351
Lamotrigine37$320

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Otsuka America Pharmaceutical, Inc.Rexulti, Abilify Maintena$157$50,24930 claims
Johnson & JohnsonInvega Sustenna$308$44,08515 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 6,258 family providers in Georgia.

Other family in Athens

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →